scripintelligence
10 March 2011
Anju Ghangurde
aghangurde@yahoo.com
GlaxoSmithKline has enacted significant price cuts for its breast cancer drug Tykerb (lapatinib) and the cervical cancer vaccine Cervarix in the Indian market, as part of its efforts to broaden access to the products through a flexible pricing approach.
GSK told Scrip that the price…
Read More
Leave a Reply